FTUS
VRTX icon

Flow Traders U.S.’s Vertex Pharmaceuticals VRTX Stock Holding History

Flow Traders U.S.’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,029
Closed -$467K – 1319
2025
Q4 		$467K Buy
+1,029
New +$444K 0.02% 587
2025
Q1 		– Sell
-1,115
Closed -$449K – 1343
2024
Q4 		$449K Buy
+1,115
New +$517K 0.02% 625

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Flow Traders U.S.'s VRTX Position: Q1 2026 in Review

Flow Traders U.S. sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 1,029 shares — an estimated $467K sold.

Flow Traders U.S. first reported a position in VRTX in Q4 2024 and held it in 2 quarters. The position peaked at $467K in Q4 2025. 1,689 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Flow Traders U.S. reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Flow Traders U.S. sold 1,029 Vertex Pharmaceuticals shares in Q1 2026, an estimated $467K.
  • Flow Traders U.S. first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Flow Traders U.S.'s Vertex Pharmaceuticals position peaked at $467K in Q4 2025.
  • 1,689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Flow Traders U.S.'s 13F filing for Q1 2026, filed 15 May 2026.